Repositorio UFRO · Omeka S

An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia

Primer Autor	Buendia, Jefferson Antonio
Co-autores	Vallejos, Carlos Pichon-Riviere, Andres
Título	An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Alternative Title	An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Editorial	INST NACIONAL SALUD
Revista	BIOMEDICA
Lenguaje	en
Resumen	Objective: Trastuzumab (Herceptin (R)), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing countries. This study assesses the cost-effectiveness of adjuvant trastuzumab treatment in Colombia. Methods: A Markov health-state transition model was built to estimate clinical and economic outcomes in HER2-positive breast cancer with or without 12 months trastuzumab adjuvant chemotherapy over a lifetime perspective with annual transition cycles. The model incorporated five health states (disease-free, local recurrence, distant recurrence, cardiac failure, and death). Baseline event rates and 3-year hazard ratio (HR= 0.51, IC 95% 0.44-0.59; p< 0.0001) were derived from 4-year follow up of the N9831 and NSABP B-31 trial. Costs and utility weights were obtained from the literature and were discounted by 5% annually. Results: The model showed that the utilization of adjuvant trastuzumab treatment in early breast cancer can prolong 0.80 quality-adjusted life-years (QALY), compared with standard chemotherapy, an incremental cost-effectiveness ratio (ICER) of US$ 71,491 per QALY gained. Conclusion: The results suggest that 1-year adjuvant Trastuzumab treatment is not cost-effective in Colombia, using the definition of WHO cost-effectiveness threshold of 3 times GDP per capita.
Tipo de Recurso	Artículo original
doi	10.7705/biomedica.v33i3.832
Formato Recurso	pdf
Palabras Claves	breast cancer Human Epidermal Growth Factor Receptor 2-Positive Colombia COST-EFFECTIVENESS ANALYSIS FOLLOW-UP THERAPY CHEMOTHERAPY PERSPECTIVE AMERICA cáncer de mama Receptor 2 del factor de crecimiento epidérmico humano positivo Colombia ANÁLISIS DE COSTO-EFICACIA SEGUIMIENTO TERAPIA QUIMIOTERAPIA PERSPECTIVA AMÉRICA
Ubicación del archivo	http://dx.doi.org/10.7705/biomedica.v33i3.832
Materias	breast cancer Human Epidermal Growth Factor Receptor 2-Positive Colombia COST-EFFECTIVENESS ANALYSIS FOLLOW-UP THERAPY CHEMOTHERAPY PERSPECTIVE AMERICA cáncer de mama Receptor 2 del factor de crecimiento epidérmico humano positivo Colombia ANÁLISIS DE COSTO-EFICACIA SEGUIMIENTO TERAPIA QUIMIOTERAPIA PERSPECTIVA AMÉRICA
Disciplinas de la OCDE	Oncología Política de Salud y Servicios Economía
Título de la cita (Recomendado-único)	An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Revista/Libro	BIOMEDICA
Tipo de ruta	diamante verde
Access Rights	acceso abierto
Derechos de acceso	acceso abierto
Identificador alternativo	PMID 24652177
Idioma	en
Identificador del recurso (Mandatado-único)	Artículo original
Versión del recurso (Recomendado-único)	versión publicada
Editorial	INST NACIONAL SALUD
ISSN	0120-4157
Página de inicio (Recomendado-único)	411
Página final (Recomendado-único)	417
Categoría WOS	Medicina Tropical Tropical Medicine
Formato	pdf
Id de Web of Science	WOS:000329817100010